Paul Bonanos

San Francisco

Biopharma Intelligence at BioCentury

I write some, I edit some

Featured in: Favicon

biocentury.com Favicon

billboard.com

Articles

Insmed’s hypertension readout spurs $750M follow-on: Public Equity Report

2 weeks ago | biocentury.com | Paul Bonanos

ARTICLE | FinancePlus: Financings for Enliven, Cabaletta, Keymed and ADC Therapeutics; a planned IPO for Caris; and Odyssey’s withdrawn listing By Paul Bonanos, Director of Biopharma Intelligence, and Meredith Durkin Wolfe, Director of ResearchA hypertension readout that propelled a lift in Insmed’s share price helped the company raise $750 million in the year’s largest follow-on by a NASDAQ-listed biotech. Shares of Insmed Inc.
Spain’s biggest venture round yet goes to Splicebio: Venture Report

2 weeks ago | biocentury.com | Paul Bonanos

ARTICLE | FinancePlus: Scorpion spinout Antares raises $177M series A, French biotechs Elkedonia and Enterome raise venture cash and more By Paul Bonanos, Director of Biopharma Intelligence, and Meredith Durkin Wolfe, Director of ResearchA $135 million series B round will make Splicebio the best-funded biotech start-up ever in Spain, allowing the company to advance its clinical program for Stargardt disease while also driving its earlier-stage pipeline.
Cross-border pain play Allay refuels for next trial: BioCentury’s weekly Finance Report

3 weeks ago | biocentury.com | Paul Bonanos

ARTICLE | FinancePlus: Series A for Israeli start-up Kamari and follow-ons for Merus, Kelun, Trevi By Paul Bonanos and Stephen Hansen, Directors of Biopharma Intelligence, and Jeff Cranmer, Executive EditorThis week’s handful of venture fundings included a series D round for a Singapore-California pain company on the cusp of Phase III testingand a series A for an Israeli start-up with a potential first-in-class asset for rare skin diseases.
Lilly’s gain in pain via Siteone takeout: Deals Report

3 weeks ago | biocentury.com | Paul Bonanos

ARTICLE | DealsPlus: Grin chooses Angelini as ex-North America partner for clinical asset to treat rare neurodevelopment disorder, and more By Paul Bonanos, Director of Biopharma Intelligence, and Meredith Durkin Wolfe, Director of ResearchMultibillion-dollar licensing and M&A deals attracted some of the biggest headlines this week, as did presentations at the American Society of Clinical Oncology meeting.
$9.1B Blueprint takeout gives Sanofi a growth driver in rare disease

3 weeks ago | biocentury.com | Paul Bonanos

ARTICLE | DealsPaul Hudson’s ninth billion-dollar deal as CEO gives pharma approved drug for systemic mastocytosis By Paul Bonanos, Director of Biopharma IntelligenceWith its purchase of Blueprint, long considered a prime M&A target, Sanofi will gain an approved drug for a rare immunological disorder as well as a pipeline that could address a broader swath of inflammatory diseases. The French pharma is paying $129 per share, or about $9.1 billion up front, to acquire Blueprint Medicines Corp.
Wave of biopharma listings on East Asian markets: Public Equity Report

4 weeks ago | biocentury.com | Paul Bonanos

ARTICLE | FinancePlus: Taysha parlays FDA update into a rarity, a follow-on financing. And more By Jeff Cranmer, Executive Editor, and Paul Bonanos, Director of Biopharma IntelligenceA flurry of new listings in Hong Kong and South Korea is energizing Asia’s public equity markets. Tuesday marked the third listing of the year on the Hong Kong stock market’s 18A biotech chapter, with Pegbio Co. Ltd.
Atlas-incubated Vima launches with $60M: Venture Report

4 weeks ago | biocentury.com | Paul Bonanos

ARTICLE | FinancePlus: Grin raises cash as it strikes territorial deal with Angelini; a nine-figure round for Glycoera; and more By Paul Bonanos, Director of Biopharma IntelligenceA syndicate led by Atlas Venture launched a new start-up addressing movement disorders, while two other companies garnered nine-figure venture rounds to fuel their clinical plans.
Green shoots in Hong Kong as Jiangsu Hengrui, Mirxes list on HKSE

1 month ago | biocentury.com | Paul Bonanos

ARTICLE | FinancePlus: Cellcentric, Repronovo, Fore raise venture rounds By Paul Bonanos, Director of Biopharma Intelligence, and Jeff Cranmer, Executive Editor At a time when the NASDAQ biotech IPO window is all but closed, the Hong Kong exchange is suddenly stirring, with a pair of listings this week and another poised to price Monday. Jiangsu Hengrui Pharmaceutical Co. Ltd. (Shanghai:600276; HKEX:1276) priced its Hong Kong listing this week to raise HK$9.9 billion (US$1.3 billion).
Zealand vet Hansen latest add to Augustine’s C-suite

1 month ago | biocentury.com | Paul Bonanos

ARTICLE | Management TracksPlus: New CFO for Freenome, Porges leaving Schroedinger By Paul Bonanos, Director of Biopharma Intelligence, and Jeff Cranmer, Executive Editor Augustine Therapeutics B.V. is continuing to build its C-suite in the wake of its €78 million ($85 million) series A round, announced in March. Its latest hire, CSO Rie Schultz Hansen, arrives from Aelin Therapeutics B.V., where she was CSO; she also spent nearly 12 years at Zealand Pharma A/S (NASDAQ:ZEAL).
In biggest licensing deal yet for a China asset, Pfizer takes rights to 3SBio’s bispecific

1 month ago | biocentury.com | Paul Bonanos

ARTICLE | DealsLatest agreement in the PD-(L)1 x VEGF space has pharma paying $1.25B up front for candidate headed to Phase III in China, first U.S. trial By Paul Bonanos, Director of Biopharma IntelligenceIn the latest and largest deal between a China-based biotech and a larger biopharma for a bispecific with broad potential in oncology, Pfizer is paying 3SBio $1.25 billion up front for most global rights to a clinical therapy that targets PD-1 and VEGF to treat a range of solid tumors.